# Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

> **NCT02500550** · PHASE2 · COMPLETED · sponsor: **Kiadis Pharma** · enrollment: 15 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** ATIR101
- **PROCEDURE:** Haploidentical hematopoietic stem cell transplantation (HSCT)
- **PROCEDURE:** TBI regime
- **PROCEDURE:** Non-TBI regime

## Key facts

- **NCT ID:** NCT02500550
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-09
- **Primary completion:** 2018-07
- **Final completion:** 2018-12-17
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500550, "Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02500550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*